Last reviewed · How we verify
Recombinant grass pollen
Recombinant grass pollen allergen extract desensitizes the immune system to grass pollen by inducing immune tolerance through repeated controlled exposure.
Recombinant grass pollen allergen extract desensitizes the immune system to grass pollen by inducing immune tolerance through repeated controlled exposure. Used for Grass pollen-induced allergic rhinitis and/or allergic asthma.
At a glance
| Generic name | Recombinant grass pollen |
|---|---|
| Sponsor | Allergopharma GmbH & Co. KG |
| Drug class | Allergen immunotherapy |
| Target | Grass pollen allergens (recombinant) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This recombinant allergen immunotherapy product contains engineered grass pollen proteins designed to shift immune responses from allergic (Th2-mediated) to tolerant (Treg-mediated) pathways. By administering gradually increasing doses of the recombinant allergen, the therapy aims to induce immune tolerance and reduce allergic symptoms upon natural grass pollen exposure. This approach is characteristic of allergen-specific immunotherapy (AIT) for IgE-mediated grass pollen allergy.
Approved indications
- Grass pollen-induced allergic rhinitis and/or allergic asthma
Common side effects
- Local injection site reactions (itching, swelling, erythema)
- Oral allergy syndrome or local oral symptoms
- Systemic allergic reactions
- Anaphylaxis
Key clinical trials
- Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response (PHASE2)
- Phase II Study of Grass Pollen Allergy Vaccine BM32 (PHASE2)
- Skin Test Study of BM32 (PHASE1, PHASE2)
- 2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma (PHASE3)
- Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma (PHASE3)
- Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens (PHASE2)
- Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis (PHASE3)
- Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant grass pollen CI brief — competitive landscape report
- Recombinant grass pollen updates RSS · CI watch RSS
- Allergopharma GmbH & Co. KG portfolio CI